4//SEC Filing
Anzalone Christopher Richard 4
Accession 0001628280-25-017592
CIK 0000879407other
Filed
Apr 10, 8:00 PM ET
Accepted
Apr 11, 6:20 PM ET
Size
12.8 KB
Accession
0001628280-25-017592
Insider Transaction Report
Form 4
Anzalone Christopher Richard
DirectorPresident and CEO
Transactions
- Sale
Common Stock
2025-04-09$9.93/sh−35,305$350,579→ 4,027,072 total - Sale
Common Stock
2025-04-10$10.87/sh−50,000$543,500→ 3,972,055 total - Sale
Common Stock
2025-04-09$11.76/sh−1,617$19,016→ 4,022,055 total - Sale
Common Stock
2025-04-09$10.75/sh−3,400$36,550→ 4,023,672 total - Sale
Common Stock
2025-04-11$11.49/sh−50,800$583,692→ 3,921,255 total
Footnotes (5)
- [F1]Sale of securities to cover taxes associated with the vesting of restricted stock awards
- [F2]The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $ 9.67 to $ 10.50, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
- [F3]Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.
- [F4]The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $ 10.51 to $ 11.44, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
- [F5]The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $ 11.49 to $ 12.08, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
Documents
Issuer
ARROWHEAD PHARMACEUTICALS, INC.
CIK 0000879407
Entity typeother
Related Parties
1- filerCIK 0001423029
Filing Metadata
- Form type
- 4
- Filed
- Apr 10, 8:00 PM ET
- Accepted
- Apr 11, 6:20 PM ET
- Size
- 12.8 KB